364 related articles for article (PubMed ID: 32200813)
1. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results.
; ; Martin DF; Maguire MG; Fine SL; Ying GS; Jaffe GJ; Grunwald JE; Toth C; Redford M; Ferris FL
Ophthalmology; 2020 Apr; 127(4S):S135-S145. PubMed ID: 32200813
[TBL] [Abstract][Full Text] [Related]
2. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
; Martin DF; Maguire MG; Fine SL; Ying GS; Jaffe GJ; Grunwald JE; Toth C; Redford M; Ferris FL
Ophthalmology; 2012 Jul; 119(7):1388-98. PubMed ID: 22555112
[TBL] [Abstract][Full Text] [Related]
3. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study.
Kertes PJ; Galic IJ; Greve M; Williams RG; Rampakakis E; Scarino A; Sheidow T
Ophthalmology; 2019 Jun; 126(6):841-848. PubMed ID: 30677465
[TBL] [Abstract][Full Text] [Related]
4. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
[TBL] [Abstract][Full Text] [Related]
5. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
6. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
7. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
; Chakravarthy U; Harding SP; Rogers CA; Downes SM; Lotery AJ; Wordsworth S; Reeves BC
Ophthalmology; 2012 Jul; 119(7):1399-411. PubMed ID: 22578446
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
Berg K; Pedersen TR; Sandvik L; Bragadóttir R
Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R;
JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148
[TBL] [Abstract][Full Text] [Related]
10. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
Ying GS; Huang J; Maguire MG; Jaffe GJ; Grunwald JE; Toth C; Daniel E; Klein M; Pieramici D; Wells J; Martin DF;
Ophthalmology; 2013 Jan; 120(1):122-9. PubMed ID: 23047002
[TBL] [Abstract][Full Text] [Related]
11. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
Bro T; Hägg S
Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
[TBL] [Abstract][Full Text] [Related]
12. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG;
Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
Daniel E; Shaffer J; Ying GS; Grunwald JE; Martin DF; Jaffe GJ; Maguire MG;
Ophthalmology; 2016 Mar; 123(3):609-16. PubMed ID: 26681392
[TBL] [Abstract][Full Text] [Related]
14. Simulating an Anti-Vascular Endothelial Growth Factor Switch in Neovascular Age-Related Macular Degeneration: A HARBOR Subanalysis.
Zarbin M; Tsuboi M; Hill LF; Stoilov I
Ophthalmology; 2019 Jun; 126(6):849-855. PubMed ID: 30641096
[TBL] [Abstract][Full Text] [Related]
15. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
; Maguire MG; Martin DF; Ying GS; Jaffe GJ; Daniel E; Grunwald JE; Toth CA; Ferris FL; Fine SL
Ophthalmology; 2016 Aug; 123(8):1751-1761. PubMed ID: 27156698
[TBL] [Abstract][Full Text] [Related]
16. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
Rahimy E; Rayess N; Ho AC; Regillo CD
Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
[TBL] [Abstract][Full Text] [Related]
17. Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial.
Daniel E; Maguire MG; Grunwald JE; Toth CA; Jaffe GJ; Martin DF; Ying GS;
JAMA Ophthalmol; 2020 May; 138(5):510-518. PubMed ID: 32191267
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.
Holz FG; Oleksy P; Ricci F; Kaiser PK; Kiefer J; Schmitz-Valckenberg S;
Ophthalmology; 2022 Jan; 129(1):54-63. PubMed ID: 33957183
[TBL] [Abstract][Full Text] [Related]
19. EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS.
Rahimy E; Ying GS; Pan W; Hsu J
Retina; 2019 Apr; 39(4):636-647. PubMed ID: 29517580
[TBL] [Abstract][Full Text] [Related]
20. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry.
Rao P; Lum F; Wood K; Salman C; Burugapalli B; Hall R; Singh S; Parke DW; Williams GA
Ophthalmology; 2018 Apr; 125(4):522-528. PubMed ID: 29146306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
